Immune checkpoint inhibitors, specifically anti-CTLA4, anti-PD1, and anti-PDL-1 antibodies, are commonly used to treat skin cancers, including melanoma, SCC, BCC, and Merkel cell carcinoma. This evidence concerns the gene CD274 and skin neoplasm.